Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Multiple Center, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

Next Previous
X
Search
Trial Profile

A Phase I, Multiple Center, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CM 313 (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
  • Indications Lymphoma; Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors KeyMed Biosciences

    • Most Recent Events

    • 15 Jun 2023 Results ( As of October 10, 2022, n=34) assessing safety and preliminary efficacy of CM313 in adult patients (pts) with RRMM orrelapsed/refractory lymphoma presented at the 28th Congress of the European Haematology Association
    • 30 Mar 2022 According to a KeyMed Biosciences media release, dose-escalation trial is expected to be completed in the first half of 2022.
    • 08 Apr 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top